Skip to main content

Table 3 Number (%) of patients who had at least one measure of LDLC <70 mg/dl on Alirocumab or Evolocumab for 24 weeks

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

  HeFH only (n = 25) Entry LDLC 25th, 50th, 75th%tile: [149, 177, 220 mg/dl] CVD only (n = 25) [104, 131, 148 mg/dl] HeFH & CVD (n = 22) [122, 169, 214 mg/dl] Total cohort (n = 72) [123, 149, 193 mg/dl]
Alirocumab 75 mg/2 weeks (n = 25) 2/5 (40%) 12/14 (86%) 5/6 (83%) 19/25 (76%)
Alirocumab 150 mg/2 weeks (n = 15) 2/4 (50%) 3/3 (100%) 6/8 (75%) 11/15 (73%)
Evolocumab 140 mg/2 weeks (n = 32) 8/16 (50%) 7/8 (88%) 3/8 (38%) 18/32 (56%)
All 3 treatment groups (n = 72) 12/25 (48%) 22/25 (88%) 14/22 (64%) 48/72 (67%)